• Mashup Score: 0

    Diagnostic criteria for Alzheimer’s disease were revised only five years ago, but the field has learned a lot since then. At the Alzheimer’s Association International Conference, held last month in Amsterdam, Clifford Jack of the Mayo Clinic in Rochester, Minnesota, proposed updates to the current “ATN” system. Like the 2018 criteria, the new ones are the product of a joint National Institute on Aging-Alzheimer’s Association working group Jack leads. The draft criteria take into account recent discoveries

    Tweet Tweets with this article
    • Revised Again: #Alzheimer's Diagnostic Criteria Get Another Makeover https://t.co/cfzvjI5Llc #amyloid #tau #amyloidPET #tauPET #cognition #memory #MCI #plaques #tangles #stages #PM101 https://t.co/ti3mJ7xOJB

  • Mashup Score: 1

    Alzheimer’s disease, one of the most common neurodegenerative diseases, leads to progressive loss of memory and autonomy. It is characterised by the accumulation of neurotoxic proteins in the brain, namely amyloid plaques and tau tangles. Due to the silent development of pathology over decades, very early diagnosis is of utmost importance to be able to take action as early as possible in the disease process. A team from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) has demonstrated that tau PET – a novel imaging technique for visualising the tau protein – can predict cognitive decline in patients much better than the imaging techniques normally used. These results, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, argue in favour of the rapid introduction of tau PET into the clinical routine to provide patients with early and individualised solutions.

    Tweet Tweets with this article
    • A @UNIGEnews team demonstrates the value of #imaging to detect the presence of #tau #protein in the #brain to predict cognitive decline due to #Alzheimer’s disease https://t.co/ATokxHwMhT

  • Mashup Score: 4

    This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.

    Tweet Tweets with this article
    • Among patients with early symptomatic #AlzheimerDisease and #amyloid and #tau pathology, #donanemab treatment significantly slowed clinical progression at 76 weeks TRAILBLAZER 2 Trial https://t.co/ewUqwm1lMR #AAIC23 https://t.co/h1LHUCCtKd